08.04.2025 23:25:00
|
Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022
The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the year.The vaccine maker's sales continue to struggle years after its top line exploded during the COVID-19 pandemic. More recently, the conspicuous exit of a top Food and Drug Administration (FDA) official has darkened investor sentiment.The company's revenues have cratered now that the coronavirus pandemic no longer rages. Moderna's 2022 sales of $19.3 billion seem like a distant memory. The company delivered just $3.2 billion in 2024, as its year-end and Q4 earnings released in early January showed a more than 50% decline year over year. Results across the board disappointed investors by failing to meet expectations. Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Moderna Incmehr Nachrichten
11.06.25 |
Börse New York: S&P 500 mit Gewinnen (finanzen.at) | |
09.06.25 |
Börse New York in Grün: S&P 500 beginnt Handel im Plus (finanzen.at) | |
06.06.25 |
Freundlicher Handel in New York: S&P 500 letztendlich in Grün (finanzen.at) | |
06.06.25 |
Gute Stimmung in New York: S&P 500 notiert am Nachmittag im Plus (finanzen.at) | |
05.06.25 |
S&P 500-Wert Moderna-Aktie: So viel Verlust hätte eine Investition in Moderna von vor einem Jahr bedeutet (finanzen.at) | |
05.06.25 |
Verluste in New York: S&P 500 zum Handelsstart im Minus (finanzen.at) | |
30.05.25 |
Börse New York in Rot: S&P 500 zum Start des Freitagshandels leichter (finanzen.at) | |
28.05.25 |
Börse New York in Rot: S&P 500 verbucht zum Handelsstart Abschläge (finanzen.at) |
Analysen zu Moderna Incmehr Analysen
19.11.24 | Moderna Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
13.09.24 | Moderna Underweight | JP Morgan Chase & Co. | |
05.08.24 | Moderna Sector Perform | RBC Capital Markets | |
12.01.24 | Moderna Outperform | RBC Capital Markets | |
03.11.23 | Moderna Buy | Goldman Sachs Group Inc. |